赛伦斯治疗

最新新闻

• 评级变动
  BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2025/6/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Medline, Inc. Class A (MDLN) and Silence Therapeutics (SLN)
  TipRanks · 2026/2/26
• 评级变动
  Goldman Sachs Initiates Silence Therapeutics(SLN.US) With Sell Rating, Announces Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2025/3/4
• Silence Therapeutics Expects Offering to Close on or About Aug. 13 SLN
  Dow Jones · 2026/8/12
• 评级变动
  Cantor Fitzgerald Initiates Silence Therapeutics(SLN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/24
• H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Silence Therapeutics (SLN) Receives a Buy From H.C. Wainwright
  TipRanks · 2026/5/27
• 评级变动
  Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  H.C. Wainwright Reaffirms Their Buy Rating on Silence Therapeutics (SLN)
  TipRanks · 2026/4/7
• 评级变动
  William Blair Maintains Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $5.5
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• William Blair Maintains Silence Therapeutics(SLN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Jefferies Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2025/2/28
• 评级变动
  Goldman Sachs Maintains Silence Therapeutics(SLN.US) With Sell Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2025/5/10
• A Quick Look at Today's Ratings for Silence Therapeutics(SLN.US), With a Forecast Between $27 to $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  William Blair Initiates Silence Therapeutics(SLN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2025/2/28
• 评级变动
  BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Cuts Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2025/3/5

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。